Site icon Impactiviti

Impactiviti Daily 041510 – Today’s Top Pharma News



Novartis announces a major US reorganization, including re-aligned business units, and cuts. Ouch.

Crystal ball – what will be the biggest drug(s) in 2014? Here are some educated guesses.

Use Remicade early in Crohn’s, the results say – “The results are pretty definitive,” Sandborn told MedPage Today. “Most patients should receive infliximab combination therapy as the most effective strategy.“…more

Genzyme‘s Campath for MS:  preliminary data look quite promising – Data presented on Wednesday at the annual meeting of the American Academy of Neurology showed that after four years, 71 percent of patients had no relapse or worsening of disability. That compares with 35 percent for patients taking Rebif, a rival drug made by EMD Serono, an affiliate of Germany’s Merck KGaA and Pfizer Incmore


ANY Pharma sales training – The Impactiviti Partner Network is your resource if you’re looking for a great training provider. We “matchmake” best-in-class partners to meet your training needs – at no cost to you!  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


I’m Restless – how about you?


Come out of your shell. Cool photos – just trust me and look.


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)


Exit mobile version